Navigation Links
Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
Date:9/5/2008

Company Named 2008 Medical Products Industry Leader

DEERFIELD, Ill., Sept. 5 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) announced today that it has been named 2008 Medical Products Industry Leader of the Dow Jones Sustainability World Index (DJSI World) and the Dow Jones Sustainability North America Index (DJSI North America). This marks the tenth consecutive year that the company has been listed in the DJSI and the seventh year the company has been named Medical Products Industry Leader since the launch of the DJSI in 1999.

Baxter's leadership position resulted from best scores across a number of performance areas including bioethics, codes of conduct, environmental policy/management, occupational health and safety, and social and environmental reporting.

"We believe our efforts in sustainability enhance shareholder value by making Baxter a more competitive company," said Robert L. Parkinson, Jr., Baxter's chairman and chief executive officer. "Baxter's approach to sustainability inspires innovation and discipline, and reflects the quality of our people and our company culture."

The Dow Jones Sustainability indices, derived from the Dow Jones Global Index, are the world's first benchmarks tracking the financial performance of leading sustainability-driven companies worldwide. The DJSI World Index tracks the financial performance of the top 10 percent of the 2,500 largest companies in the Dow Jones Global Index in terms of social, economic and environmental performance. The DJSI North America Index includes the top 20 percent in each of 57 sectors out of the largest 600 North American companies in the Dow Jones Global Index.

In addition to Baxter's inclusion in the DJSI, the c
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. Baxter Declares Quarterly Dividend
3. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
4. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
5. Baxters Board of Directors Declares Quarterly Dividend
6. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
7. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
8. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
9. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
10. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
11. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... 4 Researchers are taking a closer...) pathway as studies continue to demonstrate that ...growth, reports Genetic Engineering & Biotech...iogenesis, cell growth, differentiation, and survi...athway, which plays a key role in cancer, accordin...
(Date:12/4/2008)...ecember 4 AC Immune SA, a leader,... today that the World,Economic Forum has elected ...mplishments as an innovation leader and for its br...ct on business and society. , Furthermore, ... clinical,milestones in the development of innova...
(Date:12/4/2008).... 4 A 60-year-old,prost... first person in France,to be treated using Rapid...YSE: VAR ) for fast and precise forms of intensi...atments at the CRLC Val D,Aurelle - Paul Lamarque ...aster than conventional IMRT,treatments. Dr. Pasc...
(Date:12/4/2008)...f., Dec. 4 Peregrine P...nced that it will release its financial results fo...er 10, 2008 at 7:00 a.m. EST and will host a confe...1:30 a.m. EST on the same day. , , Peregri...lts for the second quarter ended October 31, 2008 ...
Breaking Biology Technology:GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research 2Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2
...on, Wis. - Alfalight, Inc. , a Madison-based man...l, defense, and telecommunications markets, has be... the Super High Efficiency Diode Sources program, ...ts Agency. , ,The overall goal of the project is ...-- to lower the ambient heat emitted from a laser ...
...land, Ohio - A new report of health care sector v... investments in the first half of 2005, but its po...nds begin a new cycle. , ,The report was compiled...gement counseling service specializing in the heal...d this report last quarter is we felt like a lot o...
...e are the so-called Dog Days of summer. Business s...week, most companies have entered a state of suspe...eptember. People relax. The outdoors beckons. Fami..., ,Or does it? , ,After a rare weekend away from e...my inbox and a to-do list that had miraculously gr...
...sha, Wis. -- Cummins, Inc. of Columbus, Ind., w...rt of its global supply chain strategy initiative,...use Waukesha-based RedPrairie,s warehouse manageme...visions. In subsequent rollouts, the divisions wil...agement, slotting, real-time transportation optimi...
Other Biology Technology:Alfalight garners $1.4 million defense funding for diode program 2Wisconsin ranks low in mid-year health care capital investment report 2Wisconsin ranks low in mid-year health care capital investment report 3Leaving it all behind 2
(Date:12/3/2008)...a well-known fact in drug trials that individuals ... as to the active drug. On the other hand, it is ...etter from placebos. A team of researchers from U...ow found gene variants that can impact the placebo...rizes those who respond to placebos. , The study...
(Date:12/3/2008)...i-institution team of investigators led by researc...ity of Southern California (USC) has received $19 ... Mental Health (NIMH) for a groundbreaking effort ...s of patients in order to study the genetic risks ...SC Center for Genomic Psychiatry and Massachusetts...
(Date:12/3/2008)...onide sprays can be regarded as safe for pregnancy...d though , Women can usually keep using the sa...egnant. Budesonide sprays are the best studied and...ential medicines are necessary however. According ... in Health Care (IQWiG), more data from trials cou...
(Date:12/2/2008)...land, Wash. -- DNA sequencing is easier than ever,...p. An award-winning computer program now shows tha... and intuitive, helping researchers find hidden re...rchers from the Department of Energy,s Pacific Nor... for their entry at the Supercomputing ,08 High Pe...
Breaking Biology News(10 mins):Genes determine whether sugar pills work 2USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 2USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 3Pregnant women with asthma can be more confident about some medicines 2PNNL researchers earn top honors at Supercomputing conference 2PNNL researchers earn top honors at Supercomputing conference 3Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 1Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 2Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 3Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 4Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 5Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 6Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 7Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2092 8China Yingxia International Inc Reports First Quarter 2008 Results 19568 1China Yingxia International Inc Reports First Quarter 2008 Results 19568 2China Yingxia International Inc Reports First Quarter 2008 Results 19568 3China Yingxia International Inc Reports First Quarter 2008 Results 19568 4China Yingxia International Inc Reports First Quarter 2008 Results 19568 5China Yingxia International Inc Reports First Quarter 2008 Results 19568 6China Yingxia International Inc Reports First Quarter 2008 Results 19568 7China Yingxia International Inc Reports First Quarter 2008 Results 19568 8China Yingxia International Inc Reports First Quarter 2008 Results 19568 9BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor BSI 201 at 40th American Society of Clinical Oncology Annual Meeting 2089 1BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor BSI 201 at 40th American Society of Clinical Oncology Annual Meeting 2089 2BIO key 28R 29 Reports First Quarter 2008 Results 3338 1BIO key 28R 29 Reports First Quarter 2008 Results 3338 2BIO key 28R 29 Reports First Quarter 2008 Results 3338 3
...erpool have discovered how fish have evolved over ...ifferent water depths. , A research team led by D...t the School of Biological Sciences, has revealed ...ped a way of floating at certain water levels usin...igated the mechanism that allows fishes to keep th...
...niversity in St. Louis has proposed that evolution... development rather than physical processes, such ...ngton University assistant professor of geomicrobi...ciences in Arts & Sciences, studying Cyanobact...ioxide to produce oxygen and biomass ?has conclude...
...argeted radiotherapy, on a cellular scale. Antibod...eek out, bind to and kill cancerous cells. Provide...l surface between normal and cancerous cells; this...eatment for lymphoma that takes a fraction of the ...ffects caused tumors to shrink in 95 percent of pa...
...rtant chemical in the brain,s neuronal machinery t...ioid drugs like morphine and heroin. , They belie...ansporter--could relieve some of the early physica..., uncontrolled shaking, and jumpiness. Such drugs ...behavioral techniques aimed at helping addicts kic...
Other Biology News:Scientists discover how fish evolved to float at different sea depths 2Family trees of ancient bacteria reveal evolutionary moves 2Family trees of ancient bacteria reveal evolutionary moves 3New Treatment Rivals Chemotherapy For Lymphoma, Study Finds 2New Treatment Rivals Chemotherapy For Lymphoma, Study Finds 3Key Trigger Of Opioid Withdrawal Symptoms Found 2
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals .
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals .
...e derived from an internal region of human mouse a...FT1 RAPT1). Specificity: Specific for the human m...arget band at ~235 kDa. Reactivity: Human (positi...e homology reactivity with mouse and rat is expect...
Biology Products: